*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Donald Bejleri
BME PhD Defense Presentation
Date: August 14th, 2020
Time: 9:00-11:00am
Location: https://bluejeans.com/873706466
Committee Members:
Michael E. Davis, PhD (Biomedical Engineering) (Advisor)
Johnna S. Temenoff, PhD (Biomedical Engineering)
Julie A. Champion, PhD (Chemical and Biomolecular Engineering)
Manu O. Platt, PhD (Biomedical Engineering)
Hee Cheol Cho, PhD (Biomedical Engineering)
Title: Bioprinted Cardiac Patch Composed of Cardiac Progenitor Cells and Extracellular Matrix for Heart Repair and Regeneration
Abstract: Congenital heart defects are present in 8 of 1000 newborns, and palliative surgical therapy has increased survival rates. Despite improved outcomes, many children develop reduced cardiac function and go on to heart failure and transplantation. Human cardiac progenitor cell (hCPC) therapy has the potential to repair the pediatric myocardium through reparative factor release but suffers from limited hCPC retention and functionality. Decellularized cardiac extracellular matrix hydrogel (cECM) has improved heart function in adults while also improving CPC functionality in 2D and 3D culture. This work focuses on developing a bioprinted cardiac patch composed of native cECM and pediatric hCPCs, for use as an epicardial device in repairing the damaged myocardium. First, we develop a method to print patches with bioinks composed of cECM, hCPCs, and gelatin methacrylate (GelMA). Patch assessments include bioink printability, cellular functionality, and mechanical properties in vitro. To further tailor the reparative potential of cardiac patches, we evaluate modifying patch components, particularly cell age, matrix composition, and oxygen growth conditions. Finally, we evaluate the implantation of patches in vivo towards improvements to cardiac function in a rat model of right ventricular heart failure, compared to sham controls and cell-free patches. Assessments include hCPC retention, right ventricle function, and tissue level parameters (vessel density, cardiomyocyte hypertrophy, and fibrosis) across all treatments. The animal model evaluation shows that cell-free and neonatal hCPC-laden cECM-GelMA patches improve right ventricle function and tissue level parameters compared to other patch groups and surgical controls. cECM inclusion into patches may be the most influential parameter driving therapeutic improvements. Additionally, child hCPC patches require cECM incorporation to improve right ventricle function, compared to cECM-free child hCPC patches. Altogether, this study paves the way for clinical trials in treating pediatric heart failure using the bioprinted hCPC-GelMA-cECM patches.
